17:34 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Perceptive leads Lyra's $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
11:01 , Sep 26, 2018 |  BC Extra  |  Financial News

Perceptive leads Lyra’s $29.5M series B

Ears, nose and throat disease company Lyra Therapeutics Inc. (Watertown, Mass.) raised $29.5 million in a series B round led by Perceptive Advisors. Fellow new investors RA Capital, ArrowMark Partners and Soleus Capital also participated,...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Financial News

480 Biomedical completes venture financing

480 Biomedical Inc. , Watertown, Mass.   Business: Drug delivery   Date completed: 2015-06-01   Type: Venture financing   Raised: $10.5 million   Investors: Polaris Partners; North Bridge Venture Partners; Intersouth Partners; strategic investor  ...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Company News

Illumina, Roche deal

Roche plans to nominate up to 11 directors for election to the board of Illumina at the sequencing company's annual meeting this year as part of an unsolicited bid launched in January to acquire the...
01:29 , Feb 1, 2012 |  BC Extra  |  Company News

Roche unveils slate for Illumina

Roche (SIX:ROG; OTCQX:RHHBY) plans to nominate up to 11 directors for election to the board of Illumina Inc. (NASDAQ:ILMN) at the sequencing company's annual meeting this year as part of an unsolicited acquisition bid launched...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Financial News

480 Biomedical completes venture financing

480 Biomedical Inc. , Watertown, Mass.   Business: Drug delivery   Date completed: 10/26/11   Type: Venture financing   Raised: $15 million   Investors: Polaris Venture Partners; North Bridge Venture Partners; Intersouth Partners; and an...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Arsenal Medical cardiovascular, drug delivery news

Arsenal spun out 480 Biomedical Inc. (Watertown, Mass.) to develop Arsenal's bioresorbable scaffold technology to treat occlusive disease in the superficial femoral artery. Arsenal Medical will focus on developing its Axiocore nanofiber-based drug delivery and...